Hypoactive sexual desire disorder: inventing a disease to sell low libido

@article{Meixel2015HypoactiveSD,
  title={Hypoactive sexual desire disorder: inventing a disease to sell low libido},
  author={Antonie Meixel and Elena Yanchar and Adriane Fugh-Berman},
  journal={Journal of Medical Ethics},
  year={2015},
  volume={41},
  pages={859 - 862}
}
Condition branding is a marketing technique in which companies develop conditions concurrently with developing drugs; examples include gastro-oesophageal reflux disease, premenstrual dysphoric disorder, social anxiety disorder, erectile dysfunction and hypoactive sexual desire disorder. Although it is illegal for pharmaceutical companies to market drugs prior to regulatory approval, there are no restrictions on marketing diseases, and industry seeks to establish a disease state in the minds of… 

Transdermal Testosterone For Menopause-Related Hyposexual Desire Disorder: Current Guidelines And Provider Perceptions, Knowledge, And Practice

Hypoactive sexual desire or low libido in women are collectively referred to as hypoactive sexual desire disorder (HSDD). HSDD is estimated to occur in 10% to 15% of adult women. HSDD is likely the

Flibanserin- A Novel drug for Hypoactive Sexual Desire Disorder

Flibanserin, a novel, non-hormonal, multifunctional serotonin agonist antagonist (MSAA) was used in most of the pre-menopausal women diagnosed with Hypoactive Sexual Desire Disorder (HSDD) but its approval also faced a little scepticism.

First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women

Though a strong placebo response was demonstrated, flibanserin consistently, yet marginally, showed improvement in the number of satisfying sexual events per month and should be administered at bedtime to limit the risk for hypotension/syncope, accidental injury, and central nervous system (CNS) depression.

Problematic product management: the case of flibanserin to address women’s hypoactive sexual desire disorder

  • Enav Friedmann
  • Psychology
    International Journal of Pharmaceutical and Healthcare Marketing
  • 2022
Purpose A Viagra-inspired drug, flibanserin, was marketed to treat women’s hypoactive sexual desire disorder (HSDD). This paper aims to explore the value orientation of flibanserin as a treatment

Advise Against Flibanserin.

The harms associated with flibanserin might be acceptable in a cancer drug, but they are entirely unacceptable in a drug given to healthy women for an invented condition.

Flibanserin and Female Sexual Desire.

A Review of Recent Innovations in the Treatment of Low Sexual Desire

There is a lack of consensus as to how to conceptualize and how to treat low sexual desire in men, women, or couples and on whether to target the identified patient or the relationship.

Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women

Bremelanotide’s modest benefits on incompletely reported post-hoc measures of questionable validity in combination with participants substantially preferring to take placebo suggest that the drug is generally not useful.

References

SHOWING 1-10 OF 42 REFERENCES

Hypoactive Sexual Desire Disorder International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review

It is hypothesize that all these therapies alter central inhibitory and excitatory levels in hypoactive sexual desire disorder, and that ibanserin is the only Food and Drug Administration approved medication to treat premenopausal women with generalized acquired HSDD.

Adverse effects of drug therapies on male and female sexual function

The following considerations will show that the detection and treatment of SD should be given much more attention since drug-induced SDs occur predominantly in indications where a SD itself can be a symptom of the disease.

Sexual dysfunction in the United States: prevalence and predictors.

The results indicate that sexual dysfunction is an important public health concern, and emotional problems likely contribute to the experience of these problems.

Empowering PAs to ask their female patients about sexual health

  • R. CoxLaura Fye Moore
  • Medicine
    JAAPA : official journal of the American Academy of Physician Assistants
  • 2010
A basic knowledge of the types of female sexual dysfunction and their prevalence can help physician assistants with initiating a discussion on this vital aspect of women's health.

DSM-5 Changes in Diagnostic Criteria of Sexual Dysfunctions

Recent research has put into question the validity of the model of human sexual response proposed by Masters and Johnson and further developed by Kaplan; both the strict distinction between different phases of arousal and the linear model of sexual response were found to inadequately explain sexual behavior, particularly in women.

The marketing of a disease: female sexual dysfunction

Is a new disorder being identified to meet unmet needs or to build markets for new medications?

Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance

Tiefer highlights key steps in the "creation" of a new diagnosis, female sexual dysfunction, and of the campaign to challenge its reductionist approach to women's sexual problems.

The making of a disease: female sexual dysfunction

  • R. Moynihan
  • Psychology, Medicine
    BMJ : British Medical Journal
  • 2003
Is a new disorder being identified to meet unmet needs or to build markets for new medications?

Women's Sexual Health

Women Today: Women's sexuality, Sexual Health and Sexually Acquired Infection and Women's Health Issues: Breast Screening and Disorders of the Breast.

Ethical considerations of publication planning in the pharmaceutical industry

How industry uses publication planning to sway medical and public opinion through the medium of medical journals is described.